Calliditas Therapeutics AB (CALT)
20.13
+0.13
(+0.65%)
USD |
NASDAQ |
May 06, 16:00
19.56
-0.57
(-2.83%)
After-Hours: 20:00
Calliditas Therapeutics Total Assets (Quarterly): 184.69M for Dec. 31, 2023
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 184.69M |
| September 30, 2023 | 147.67M |
| June 30, 2023 | 157.39M |
| December 31, 2022 | 187.38M |
| September 30, 2022 | 136.31M |
| June 30, 2022 | 142.72M |
| March 31, 2022 | 145.56M |
| December 31, 2021 | 161.37M |
| September 30, 2021 | 201.14M |
| June 30, 2021 | 144.58M |
| March 31, 2021 | 159.07M |
| December 31, 2020 | 178.77M |
| Date | Value |
|---|---|
| September 30, 2020 | 160.63M |
| June 30, 2020 | 159.49M |
| March 31, 2020 | 78.22M |
| December 31, 2019 | 90.45M |
| September 30, 2019 | 85.95M |
| June 30, 2019 | 76.23M |
| March 31, 2019 | 65.12M |
| December 31, 2018 | 72.21M |
| September 30, 2018 | 77.41M |
| June 30, 2018 | 7.382M |
| March 31, 2018 | 6.839M |
| December 31, 2017 | 7.617M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
76.23M
Minimum
Jun 2019
201.14M
Maximum
Sep 2021
144.31M
Average
152.53M
Median
Total Assets (Quarterly) Benchmarks
| DBV Technologies SA | 182.99M |
| Cellectis SA | 334.27M |
| Adaptimmune Therapeutics PLC | 282.62M |
| Akari Therapeutics PLC | 4.355M |
| Biodexa Pharmaceuticals Plc | 13.43M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 151.43M |
| Shareholders Equity (Quarterly) | 33.26M |
| Debt to Equity Ratio | 2.806 |
| Current Ratio | 3.132 |
| Net Debt Paydown Yield | -1.46% |